Welcome to our dedicated page for Metsera news (Ticker: MTSR), a resource for investors and traders seeking the latest updates and insights on Metsera stock.
Metsera, Inc. (formerly NASDAQ: MTSR) generates a distinctive news profile at the intersection of biotechnology, obesity therapeutics, and large-cap pharmaceutical dealmaking. As a clinical-stage biopharmaceutical company focused on obesity and metabolic diseases, Metsera has issued frequent updates on its pipeline programs, particularly MET-097i, a fully biased, ultra-long acting GLP-1 receptor agonist with potential for monthly dosing. News coverage has highlighted Phase 2b results from the VESPER-1 and VESPER-3 trials, including dose-dependent weight loss and detailed gastrointestinal tolerability data in participants with overweight or obesity without type 2 diabetes.
Another major theme in MTSR news has been strategic transactions. Filings and press releases describe Metsera’s entry into an Agreement and Plan of Merger with Pfizer, subsequent amendment of the merger terms, and competing unsolicited proposals from Novo Nordisk A/S that were deemed “Superior Company Proposals” by Metsera’s Board. News items track the evolution of these offers, changes to cash consideration and contingent value rights (CVRs), and related litigation between Metsera and Pfizer over deal terms and regulatory considerations.
For readers following MTSR-related developments, this news stream includes: clinical trial milestones for MET-097i and its combination, oral, and prodrug programs; regulatory and antitrust steps such as early termination of the Hart-Scott-Rodino waiting period; Board determinations regarding competing bids; and the ultimate completion of Pfizer’s acquisition of Metsera and the resulting delisting of MTSR from the Nasdaq Global Select Market. Investors, analysts, and healthcare observers can use this page to review how Metsera’s scientific progress and transaction process unfolded over time.
Metsera (NASDAQ:MTSR) announced positive Phase 2b results for MET-097i, their first-in-class ultra-long acting GLP-1 receptor agonist candidate. The VESPER-1 trial demonstrated impressive placebo-subtracted weight loss of up to 14.1% after 28 weeks, with individual responses reaching 26.5%. The drug showed potentially best-in-class tolerability with minimal side effects in the VESPER-3 trial, including only 13% nausea and 11% vomiting at the highest dose.
The trials involved 239 participants in VESPER-1 and 268 subjects in VESPER-3, with doses ranging from 0.4mg to 1.2mg. Notably, the study achieved high retention rates with only 2.9% discontinuation in VESPER-1. Based on these positive results, Metsera plans to initiate Phase 3 trials in late 2025, positioning MET-097i as a potential monthly dosing option with dual-agonist-like efficacy.
Pfizer (NYSE:PFE) has announced a definitive agreement to acquire Metsera (NASDAQ:MTSR) in a deal valued at $47.50 per share in cash, representing an enterprise value of $4.9 billion. The deal includes a CVR worth up to $22.50 per share tied to clinical and regulatory milestones.
The acquisition brings Pfizer four clinical-stage incretin and amylin programs targeting obesity and cardiometabolic diseases. Key assets include MET-097i, a weekly and monthly injectable GLP-1 receptor agonist in Phase 2, and MET-233i, a monthly amylin analog in Phase 1, along with two oral GLP-1 RA candidates.
The transaction is expected to close in Q4 2025, subject to regulatory approvals and Metsera shareholder approval. This strategic move positions Pfizer in the growing obesity therapeutic area, which is associated with over 200 health conditions.
Metsera (NASDAQ:MTSR), a clinical-stage biopharmaceutical company, will present important data from its obesity treatment portfolio at the 61st EASD Annual Meeting in Vienna, Austria (September 15-19, 2025). The company will showcase three key presentations, including a late-breaking presentation on MET-233i, their ultra-long acting amylin analog.
Chief Medical Officer Steve Marso highlighted the potential of their next-generation nutrient-stimulated hormone (NuSH) therapies, both as standalone treatments and in combinations. Key presentations will feature the pharmacokinetics and weight loss results of MET-233i, and preclinical data on combining MET-233i with MET-097i, their ultra-long acting GLP-1 receptor agonist, representing a first-in-category multi-NuSH combination approach to obesity treatment.
Metsera (Nasdaq: MTSR), a clinical-stage biopharmaceutical company focused on obesity and metabolic diseases, has announced upcoming investor conference presentations. CEO Whit Bernard will present at two major healthcare conferences in September:
- Cantor Global Healthcare Conference on September 3 at 3:20-3:50 PM EDT
- Wells Fargo Healthcare Conference on September 4 at 4:30-5:05 PM EDT
Investors can access live webcasts and replays of both presentations through the Events page in the Investors & News section at investors.metsera.com.
Metsera (NASDAQ:MTSR), a clinical-stage biopharmaceutical company, reported significant progress in its Q2 2025 pipeline for obesity and metabolic disease treatments. The company highlighted positive results for two key programs: MET-097i, a monthly GLP-1 receptor agonist with Phase 3 initiation planned for late 2025, and MET-233i, a monthly amylin analog that achieved 8.4% weight loss in five weeks with a 19-day half-life.
The company maintains a strong financial position with $530.9 million in cash, providing runway into 2027. Q2 2025 saw increased R&D expenses of $60.5 million and a net loss of $68.7 million. Multiple clinical milestones are expected in late 2025, including VESPER-1 data release, 12-week monotherapy data for MET-233i, and preliminary results from their oral peptide program.
Metsera (Nasdaq: MTSR), a clinical-stage biopharmaceutical company focused on developing next-generation medicines for obesity and metabolic diseases, has announced its participation in the Bank of America 2025 Global Healthcare Conference. CEO Whit Bernard will deliver a presentation on Wednesday, May 14, 2025, from 2:20 to 2:35 P.M. PDT (5:20 – 5:35 P.M. EDT). Interested parties can access a live webcast of the presentation through the Events page in the Investors & News section of Metsera's website at investors.metsera.com.
FAQ
What is the current stock price of Metsera (MTSR)?
What is the market cap of Metsera (MTSR)?
